Maternal SARS-CoV-2 Vaccination and Infant Protection Against SARS-CoV-2 During the First 6 Months of Life

Abstract We examined the effectiveness of maternal vaccination against SARS-CoV-2 infection in 30,288 infants born at Kaiser Permanente Northern California from December 15, 2020, to May 31, 2022. Using Cox regression, the effectiveness of maternal vaccination was 85% (95% confidence interval [CI]: 67, 93), 64% (CI: 43, 78) and 57% (CI: 36,71) during the first 2, 4 and 6 months of life, respectively, in the Delta variant period. In the Omicron variant period, the effectiveness of maternal vaccination in these three age intervals was 22% (CI: -18,48), 14% (CI: -10,32) and 12% (CI: -4,26), respectively. Over the entire study period, the incidence of hospitalization for COVID-19 was lower during the first 6 months of life among infants of vaccinated mothers compared with infants of unvaccinated mothers (21/100,000 person-years vs. 100/100,000 person-years). Maternal vaccination was protective, but protection was lower during Omicron than during Delta. Protection during both periods decreased as infants aged.

[1]  M. Stockwell,et al.  Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States , 2022, JAMA network open.

[2]  P. Austin,et al.  Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes , 2022, JAMA network open.

[3]  M. Hernán,et al.  BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age , 2022, The New England journal of medicine.

[4]  A. Randolph,et al.  Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants , 2022, The New England journal of medicine.

[5]  J. Kinge,et al.  Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants , 2022, JAMA internal medicine.

[6]  W. Schaffner,et al.  Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[7]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[8]  William F. Fadel,et al.  Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[9]  G. Alter,et al.  Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection. , 2022, JAMA.

[10]  Manish M Patel,et al.  Frequency, Characteristics and Complications of COVID-19 in Hospitalized Infants , 2021, The Pediatric infectious disease journal.

[11]  William F. Fadel,et al.  Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings , 2021, The New England journal of medicine.

[12]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[13]  S. Dominguez,et al.  Risk Factors for Severe COVID-19 in Children. , 2021, The Pediatric infectious disease journal.

[14]  B. Fireman,et al.  Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season , 2020, PloS one.

[15]  A. Pollard,et al.  Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates , 2017, Vaccine.

[16]  E. Lewis,et al.  Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis , 2017, Pediatrics.